De La Rue (DLAR); discloses turnaround plan
De La Rue today disclosed the details of the turnaround plan, following the completion of three months of data-driven work by the leadership team. The plan covers three years from FY 2020/21 to FY2022/23 inclusive. In the second half of the year, the company reported satisfactory trading in both the divisions
Read more...Genesis Emerging (GSS); share price total return at 6.6%
Genesis Emerging Markets Fund announced its half-year report for the six months ended 31 December 2019. Genesis’ NAV increased 4.5% in sterling total return terms to £8.67 per participating preference share compared with a 3.1% increase in the benchmark—the MSCI Emerging Markets Total Return Index. A dividend of 14.78p per participating preference share was paid to shareholders on 13 December 2019.
Read more...CVC Credit Partners (CCPG); announces February 2020 share conversion
CVC Credit Partners European Opportunities announced the conversion of several Sterling shares into Euro shares. On the basis of the NAVs of the company’s Euro and Sterling shares as of 31 January 2020, the current conversion ratio is 1.256415 Euro shares per Sterling share.
Read more...Accsys Technologies (AXS): announce commercial agreements
Accsys announced that it has entered into an agreement with Cerdia Produktions (Cerdia), under which Accsys will take on responsibility for commercial activities under agreements with Cerdia relating to Accoya wood, which will terminate on 1 April 2020.
Read more...ReNeuron Group (RENE); reports positive long-term data in retinal clinical trial
ReNeuron Group announced positive long-term data from the ongoing phase 1/2a clinical trial of its hRPC stem cell therapy candidate in retinitis pigmentosa (RP) and plans to expand the ongoing study. Subsequent long-term efficacy data from the study continues to show meaningful clinical effect from the therapy at all time points out to 12 months post-treatment.
Read more...UIL Limited (UTL); releases unaudited half year report
UIL Limited releases its unaudited half-yearly financial report for the six months to 31 December 2019. Revenue return per ordinary share stood at 4.25p. Gearing rose to 75.1% for the period, led by an increase in gross debt and a reduction in shareholders’ funds.
Read more...Plant Health Care (PHC); proposes placing and subscription to raise a minimum of $4m
Plant Health Care announced its plan to raise a minimum of $4.0m by way of a placing of new ordinary shares at a fixed price of 8p per new ordinary share to institutional and other investors and a subscription of new ordinary shares at the issue price to institutional and other investors. The placing is to be conducted by way of an accelerated bookbuild process, which will commence immediately.
Read more...Northgate (NTG); announces completion of merger
Northgate and Redde have reached an agreement on the terms of a recommended all-share merger of Northgate and Redde. In accordance with the shareholder resolution passed by Northgate’s shareholders, Northgate was renamed Redde Northgate immediately after the scheme became effective.
Read more...BioPharma Credit (BPCR); declares an interim dividend of $0.0303 per share
BioPharma Credit has declared an interim dividend of $0.0303 per ordinary share for the financial period ending 31 December 2019. The dividend will be paid on 27 March 2020 to ordinary shareholders on the register as of 28 February 2020.
Read more...Norcros (NXR); expects South African business to generate underlying profitability for FY 2020
Norcros announced its trading update for the 10-month period ended 2 February 2020. The group continued to win market share in its major markets despite conditions remaining challenging. In the UK, the company continued to benefit from share gains in the domestic market, with overall year-on-year revenue growth similar to that achieved in H1, albeit with export performance remaining subdued.
Read more...